Securities Litigation: AstraZeneca

In re AstraZeneca Securities Litigation (Exanta)
USDC SD New York
FDA; Foreign Company

Company background

Litigation background

Lead plaintiffs

Complaint

Motion to dismiss

Supplemental authority

Order

In sum, the Court dismisses the claims of foreigners purchasing on foreign exchanges for lack of subject matter jurisdiction, and dismisses all claims against Barnevik and Mogren for lack of personal jurisdiction. The 10(b) and Rule 10b-5 claims are dismissed as to all remaining defendants because the complaint does not adequately allege scienter, and the 20(a) and 20A claims are dismissed for lack of an underlying violation.

Appeal to Second Circuit

Appeal

Lead plaintiff

Company defense

// This display the document title in the html page document.write(document.title);